OncoSec Medical Inc (ONCS)

1.76
0.04 2.10
NASDAQ : Health Care
Prev Close 1.80
Open 1.80
Day Low/High 1.72 / 1.80
52 Wk Low/High 1.36 / 6.94
Volume 113.07K
Avg Volume 145.30K
Exchange NASDAQ
Shares Outstanding 17.64M
Market Cap 32.27M
EPS -1.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

OncoSec Presents Preliminary Findings From Head And Neck Phase II Clinical Trial At EUROGIN 2016 Conference

OncoSec Presents Preliminary Findings From Head And Neck Phase II Clinical Trial At EUROGIN 2016 Conference

ImmunoPulse™ IL-12 May Lead to Increased CD8+ T-Cell Infiltration in Patients with Squamous Cell Carcinoma of the Head and Neck, Suggesting That It May Prime Responses to Anti-PD-1 Blockade

OncoSec Collaborators Present Results Of Novel T-Cell Exhaustion Marker To Predict Response To Anti-PD-1 Monotherapy

OncoSec Collaborators Present Results Of Novel T-Cell Exhaustion Marker To Predict Response To Anti-PD-1 Monotherapy

The combination of OncoSec's ImmunoPulse™ IL-12 and pembrolizumab is the first clinical trial to use this assay to select specific patients, who are unlikely to respond to monotherapy with anti-PD-1 agents

Ziopharm Subpar Cancer Therapies Can't Support Lofty Market Valuation

Ziopharm Subpar Cancer Therapies Can't Support Lofty Market Valuation

Ziopharm is its own mini biotech bubble, held aloft unjustifiably because of its interlocking relationship with Intrexon, the synthetic biology company majority-owned by R.J. Kirk.

OncoSec And Heat Biologics Present Data At The American Conference For Cancer Research (AACR) Annual Meeting

OncoSec And Heat Biologics Present Data At The American Conference For Cancer Research (AACR) Annual Meeting

Preclinical findings demonstrate that intratumoral electroporation activates tumor neoantigen-specific immune responses

OncoSec To Present At ICV Manhattan

OncoSec To Present At ICV Manhattan